Education
About Us
Working with TipRanks
Follow Us
Harrow Health Inc (HROW)
NASDAQ:HROW
HROW Stock Chart & Stats
$39.60
-$0.36(-1.00%)
At close: 4:00 PM EST
$39.60
-$0.36(-1.00%)
Day’s Range― - ―
52-Week Range$20.85 - $50.72
Previous CloseN/A
Volume51.77K
Average Volume (3M)784.84K
Market Cap
$1.49B
Enterprise Value$2.05B
Total Cash (Recent Filing)$74.29M
Total Debt (Recent Filing)$251.87M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Mar 25, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding37,037,453
10 Day Avg. Volume968,476
30 Day Avg. Volume784,839
Financial Highlights & Ratios
PEG Ratio1.97
Price to Book (P/B)17.17
Price to Sales (P/S)5.99
P/FCF Ratio-19.65
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue8.20
Enterprise Value/Gross Profit11.00
Enterprise Value/Ebitda53.31
Forecast
1Y Price Target
$72.67Price Target Upside83.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.37
Revenue Forecast (FY)$281.64M
Bulls Say, Bears Say
Bulls Say
Debt ManagementThe refinancing allows the company to extend the maturity of its debt and do so at a lower interest rate than its existing debt, while adding cash to the balance sheet for general corporate purposes.
Market PositionHarrow is advancing its position as a leader in the U.S. ophthalmic pharmaceutical market with the growth of its FDA-approved franchise.
Product ExpansionHarrow announced an agreement with Samsung Bioepis to acquire exclusive U.S. commercial rights to Byooviz and Opuviz, biosimilars for Lucentis and Eylea, respectively.
Bears Say
Pricing ChallengesVevye revenue came in below expectations despite decent sequential growth in volumes, prescribers, and market share due to a modest sequential decline in net price.
Revenue ExpectationsHarrow reported revenue of $71.6 million, relatively in line with the estimate of $71.8 million but below consensus of $73.7 million.
Revenue GuidanceManagement slightly lowered full-year revenue guidance from over $280 million to the range of $270 million to $280 million, largely driven by an inventory shortage at ImprimisRx.
Harrow Health News
HROW FAQ
What was Harrow Health Inc’s price range in the past 12 months?
Harrow Health Inc lowest stock price was $20.85 and its highest was $50.72 in the past 12 months.
What is Harrow Health Inc’s market cap?
Harrow Health Inc’s market cap is $1.49B.
When is Harrow Health Inc’s upcoming earnings report date?
Harrow Health Inc’s upcoming earnings report date is Mar 25, 2026 which is in 124 days.
How were Harrow Health Inc’s earnings last quarter?
Harrow Health Inc released its earnings results on Nov 10, 2025. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.215 by -$0.185.
Is Harrow Health Inc overvalued?
According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued.
Does Harrow Health Inc pay dividends?
Harrow Health Inc does not currently pay dividends.
What is Harrow Health Inc’s EPS estimate?
Harrow Health Inc’s EPS estimate is 0.39.
How many shares outstanding does Harrow Health Inc have?
Harrow Health Inc has 37,037,453 shares outstanding.
What happened to Harrow Health Inc’s price movement after its last earnings report?
Harrow Health Inc reported an EPS of $0.03 in its last earnings report, missing expectations of $0.215. Following the earnings report the stock price went up 13.474%.
Which hedge fund is a major shareholder of Harrow Health Inc?
Currently, no hedge funds are holding shares in HROW
Harrow Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.67 (83.51% Upside)
$72.67 (83.51% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 26.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.25%
12-Months-Change
Fundamentals
Return on Equity
-9.54%
Trailing 12-Months
Asset Growth
3.39%
Trailing 12-Months
Company Description
Harrow Health Inc
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
HROW Company Deck
HROW Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and successful product performances, particularly with VEVYE and IHEEZO, alongside significant strategic coverage wins for VEVYE. However, there were challenges with TRIESENCE's performance and potential issues with ImprimisRx that may affect future revenues.View all HROW earnings summariesHROW Stock 12 Month Forecast
Average Price Target
$72.67
▲(83.51% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
26.45% Insiders
9.94% Mutual Funds
25.22% Other Institutional Investors
27.88% Public Companies and Individual Investors